Kanada - Inggris - Health Canada

fresenius kabi canada ltd - cefuroxime (cefuroxime sodium) - powder for solution - 1.5g - cefuroxime (cefuroxime sodium) 1.5g - second generation cephalosporins

Kanada - Inggris - Health Canada

fresenius kabi canada ltd - cefuroxime (cefuroxime sodium) - powder for solution - 7.5g - cefuroxime (cefuroxime sodium) 7.5g - second generation cephalosporins

Kanada - Inggris - Health Canada

sterimax inc - cefuroxime (cefuroxime sodium) - powder for solution - 750mg - cefuroxime (cefuroxime sodium) 750mg - second generation cephalosporins

Kanada - Inggris - Health Canada

sterimax inc - cefuroxime (cefuroxime sodium) - powder for solution - 1.5g - cefuroxime (cefuroxime sodium) 1.5g - second generation cephalosporins

Kanada - Inggris - Health Canada

sterimax inc - cefuroxime (cefuroxime sodium) - powder for solution - 7.5g - cefuroxime (cefuroxime sodium) 7.5g - second generation cephalosporins

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 263mg equivalent to cefuroxime 250 mg - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to cefuroxime 250 mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

sagent pharmaceuticals - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - men

Amerika Serikat - Inggris - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin­-structure infections caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , escherichia coli , klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pneumoniae , escherichia coli , haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - mening

Kanada - Inggris - Health Canada

pharmaceutical partners of canada inc - cefuroxime (cefuroxime sodium) - powder for solution - 750mg - cefuroxime (cefuroxime sodium) 750mg - second generation cephalosporins

Kanada - Inggris - Health Canada

pharmaceutical partners of canada inc - cefuroxime (cefuroxime sodium) - powder for solution - 1.5g - cefuroxime (cefuroxime sodium) 1.5g - second generation cephalosporins